Pharma channel feed – Endpoints News

Pharma channel feed

Loxo beefs up its genetics-based cancer drug pipeline with an unusual $40M deal

8 years ago

Dynavax takes a big step toward an OK for hep B vaccine, but nagging safety issues remain

8 years ago

Biotech billionaire Soon-Shiong picks up rights to CytRx’s troubled cancer drug

8 years ago

The global rivalry for top scientific talent in biopharma R&D is about to get a lot hotter

8 years ago

Tesaro partners with Takeda in Asia, bagging a $340M deal for Zejula

8 years ago

Astellas is shuttering Agensys, axing 220 jobs and moving away from ADC tech

8 years ago

Eagle Pharma shares tank after FDA stiff-arms its application for heat stroke remedy

8 years ago

Gottlieb to delay issuing layoff notices and reassures FDA staff that Congress will reauthorize user fees

8 years ago

Biogen lays out a plan to “streamline” ops, add $400M to fund neurosciences R&D, new deals

8 years ago

Novavax makes a case for a do-over on its failed RSV vaccine — but it's an uphill climb

8 years ago

Troubled Teva brings out the ax as it cuts deep into its Israeli pharma group

8 years ago

Gilead details its case for a new HIV flagship triple, with megablockbuster potential

8 years ago

Eli Lilly offers $400M-plus deal to bag an early-stage autoimmune drug from Nektar

8 years ago

An upstart in the polyclonal antibody biz just lined up $50M for its plan to disrupt a multibillion-dollar business

8 years ago

Amgen and Novartis ID the finish line in a wicked scramble for first CGRP migraine drug OK

8 years ago

Roche punts a PhI cancer drug out of the pipeline and back to Oryzon

8 years ago

Spurned by AbbVie, Ablynx wins another Big Pharma partner offering a blockbuster prize for success

8 years ago

BIO lobbies lawmakers for new rules that expose biotech short sellers

8 years ago

Vertex shares shoot up, adding $8B in market cap after cystic fibrosis triples 'knocked it out of the park'

8 years ago

FDA OKs a new triple hep C drug from Gilead -- plus the top 10 anti-viral companies in the world

8 years ago

Eli Lilly buys itself an antibody R&D platform from Tillman Gerngross’s Adimab

8 years ago

BioMarin may have lost the battle in DMD rivalry, but it won a $35M argument with Sarepta

8 years ago

Back from the dead: Nektar hunts a blockbuster deal as opioid '181 looks less addictive than oxy

8 years ago

Puma wins big FDA OK for neratinib after running the gamut with investors

8 years ago

First page Previous page 318 319 320321322 323 324 Next page Last page